| Systemic Lupus Erythematosus |
1 |
1 |
| Lupus |
0 |
0.99 |
| Clinical Research |
0 |
0.98 |
| Healthcare and Medical Technology |
0 |
0.21 |
| Adverse Effects |
0 |
0.16 |
| Patient Safety |
0 |
0.15 |
| Otolaryngology |
0 |
0.13 |
| Psoriatic Arthritis |
0 |
0.12 |
| Arthritis |
0 |
0.11 |
| Dorsum |
0 |
0.11 |
| Acne |
0 |
0.1 |
| Biologic Therapy |
0 |
0.08 |
| Revenue and Practice Management |
0 |
0.07 |
| Upper Respiratory Tract Infection |
0 |
0.07 |
| Biomarker |
0 |
0.05 |
| Cytokines |
0 |
0.05 |
| Dermatoses |
0 |
0.05 |
| Drug Development |
0 |
0.05 |
| Europe |
0 |
0.05 |
| Fellowship |
0 |
0.05 |
| Financial Reimbursement |
0 |
0.05 |
| Geriatrics |
0 |
0.05 |
| Hand |
0 |
0.05 |
| Hospital |
0 |
0.05 |
| Interleukin |
0 |
0.05 |
| Leukemia |
0 |
0.05 |
| Lymphocytes |
0 |
0.05 |
| Lymphoma |
0 |
0.05 |
| Nasopharyngitis |
0 |
0.05 |
| NHS |
0 |
0.05 |
| Opportunistic Infection |
0 |
0.05 |
| Pharmacodynamics |
0 |
0.05 |
| Pharmacokinetics |
0 |
0.05 |
| Pruritus |
0 |
0.05 |
| Receptors |
0 |
0.05 |
| Respiratory Tract |
0 |
0.05 |
| Targeted Cancer Therapy |
0 |
0.05 |
| Tyrosine Kinase |
0 |
0.05 |
| Headache |
0 |
0.04 |
| Herpes Zoster |
0 |
0.04 |
| Psoriasis |
0 |
0.04 |
| Skin and Soft Tissue Infection |
0 |
0.04 |
| Urinary Tract Infection |
0 |
0.04 |